There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Questions and Answers
Date answered:
6 May 2025
S6W-37142
The provision of healthcare services, including medicines, is the responsibility of local NHS Health Boards, and it is for individual Health Boards to consider the implementation of any new treatment within their services in order to meet their local population needs.The Centre for Sustainable Delivery are having initial conversations about the potential to undertake Parkinson’s Disease pathway work, which we understand would help to explore and articulate pathways for therapies for advanced and complex Parkinson’s Disease.The Scottish Government has committed to investing rebates from the Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) to fund the New Medicines Fund (NMF), which provides additional top-up funding to territorial Health Boards to support the cost of introducing new medicines.
Questions and Answers
Date answered:
14 June 2023
S6W-18294
The regulations for the licensing, safety and efficacy of medicines are currently reserved to the UK Government and are the responsibility of the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Questions and Answers
Date answered:
7 December 2021
S6W-04340
The regulation of medicines and medicinal products, including Cannabis Based Products for Medicinal Use (CBPMs) is reserved to the UK Government, and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA...
Official Report
Meeting date:
4 May 2023
Meeting of the Parliament 04 May 2023
Corrected text— In secondary care, hospital electronic prescribing and medicines administration—HEPMA—is being rolled out across Scotland and has already been implemented in 11 NHS Boards.
Last updated:
23 July 2024
TCA The Windsor Framework following the Safeguarding the Union deal
There was also agreement on the sale of human medicines in NI and on customs declarations on parcels GB to NI (allowing flexibility beyond that foreseen by the Protocol).
Questions and Answers
Date answered:
19 April 2023
S6W-16721
Budget Description 2022-23 Allocation 2023-24 Allocation Percentage Movement Support for Active Travel – Capital (includes £11.073 m to bring Cycling Walking and Safer Routes up to £35 m) 113.750 152.900 34% Support for Active Travel – Resource 12.300 12.383 1% Support for Active Travel Sub-Total 126.050...
Questions and Answers
Date answered:
7 February 2023
S6W-13934
The following table sets out (b) budget against expenditure and explanations for variances that are included in the published outturn statements within the Scottish Government consolidated accounts each year. Year Budget £m Expenditure £m Comments 2016-17 266 266 No variance 2017-18 311 170 The underspend...
Questions and Answers
Date answered:
22 September 2022
S6W-10733
Mortgage to Rent Financial Year Total Subsidy Expenditure (£m) Average Subsidy Expenditure (£m) No. of Homes Purchased 2008-09 15.226 0.065 233 2009-10 19.600 0.060 303 2010-11 20.097 0.052 374 2011-12 14.500 0.041 325 2012-13 9.871 0.035 288 2013-14 8.274 0.031 228 2014-15 5.661 0...
Questions and Answers
Date answered:
1 September 2025
S6W-39892
The numbers of entrants to first degree pre-clinical medicine courses, by university, have been provided in the following table.The tables only cover those entering ‘pre-clinical medicine’ and do not include other students entering medical schools on ‘clinical medicine’ or students in continuing years of study.First degree entrants to pre-clinical medicine at Scottish Providers 2020-212021-222022-232023-24The University of Aberdeen215220280300The University of Dundee185185195230The University of Edinburgh235255285275The University of Glasgow335325295335The University of St Andrews175250190190Total1,1451,2301,2401,335Source: HESA student dataPre-clinical medicine as defined by HECOS subject classification '100276'Entrants covers new students onlyFigures have been rounded to the nearest 5Includes all domiciles of entrants S6W-39892
Questions and Answers
Date answered:
21 March 2025
S6W-35632
A conditional marketing authorisation was granted by the Medicines and Healthcare products Regulatory Agency for givinostat (Duvyzat®) on 20 December 2024.
